Are implantable cardioverter- defibrillators cost-effective?
| Autor: | Naik Am, Peter Ct |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
medicine.medical_specialty
Ventricular Tachyarrhythmias Cost-Benefit Analysis Amiodarone Ventricular tachycardia law.invention Pharmacotherapy Randomized controlled trial law Internal medicine medicine Humans In patient Ejection fraction business.industry medicine.disease Procainamide Markov Chains Defibrillators Implantable Death Sudden Cardiac cardiovascular system Cardiology Quality of Life Tachycardia Ventricular Cardiology and Cardiovascular Medicine business Electrophysiologic Techniques Cardiac Anti-Arrhythmia Agents Cardiac deaths medicine.drug |
| Zdroj: | Current cardiology reports. 2(4) |
| ISSN: | 1523-3782 |
| Popis: | Sudden cardiac deaths account for a large number of cardiovascular deaths, and ventricular tachyarrhythmias are implicated in many of these. In survivors of sudden cardiac deaths and other selected groups of patients, implantable cardioverter-defibrillators (ICDs) have been shown to have significant survival benefits in randomized controlled trials. The incremental costs for each extra year of survival conferred by ICDs were compared to the cost of antiarrhythmic drug therapy in some of these trials. In patients with nonsustained ventricular tachycardia with low ejection fraction (< 35%) and inducible sustained ventricular tachycardia on programmed electrical stimulation (nonsuppressible by procainamide), the incremental costs of ICD therapy amounted to $27,000 per life-year saved, compared with drug therapy. These costs may be acceptable increments for adaptation of the new technology in view of the definite survival advantage conferred by ICDs. Evolving technology may further reduce these costs by development of better devices with longer battery life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink